DE
About us
Company
Strategy & Mission
Management
Career
Portfolio
Marketed products
Pipeline
Immunology
Virology
Scientific Publications
Partnering
Business Development
Solv4U
Investors & ESG
Restructuring proceedings
Investment Highlights
Share information
Ad-hoc News
Financial publications
Facts & Figures
Financial Calendar
Responsibility & ESG
Annual General Meeting
Capital Transactions
IR contact
News & Publications
Corporate News
Scientific Publications
Events & Press
Downloads
DE
11. March 2021 | Corporate News
Marinomed Biotech AG Enrolls First Patients in Phase II Clinical Trial of Tacrosolv to Treat Allergic Rhinoconjunctivitis (Hay Fever)
Marinomed Biotech AG
News & Publications
Press release
The full press release is available as download here:
Marinomed Biotech AG Enrolls First Patients in Phase II Clinical Trial of Tacrosolv to Treat Allergic Rhinoconjunctivitis (Hay Fever)
(136 KB)
